Sana Biotechnology, Inc. Net Change in Cash
Sana Biotechnology, Inc. (SANA) reported Net Change in Cash of -$14.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-10
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $11.93M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$31.07M, a 171.37% decline year-over-year.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $43.54M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$16.31M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$55.33M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$5.95M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$49.92M.
- Sana Biotechnology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$74.58M, a 155.28% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.80M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $11.93M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | -$55.33M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | -$23.85M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$55.93M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$31.07M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$5.95M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | -$6.52M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $43.54M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$49.92M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | -$14.99M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$2.98M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$16.31M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$74.58M 10-K · filed 2025-03-17 | |||
| 2022-09-30 | -$88.00M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$56.68M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$64.51M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $134.90M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $315.54M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $550.33M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $625.88M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $45.14M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $69.56M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $375.38M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $9.64M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $50.36M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |